Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gevo

It's a well-known fact that the “big money” on Wall Street wants to draw retail investors' focus away from great stock deals. This is simply because if everyday investors are not buying the shares of such companies, the lack of competition enables large entities to quietly accumulate these forgotten stocks to buy at a much lower rate.

Betting Big: 3 Forgotten Stocks Primed for a Breakout

Recently, Zacks.com users have been paying close attention to InMode (INMD). This makes it worthwhile to examine what the stock has in store.

Is Most-Watched Stock InMode Ltd. (INMD) Worth Betting on Now?

Zacks.com users have recently been watching InMode (INMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

InMode Ltd. (INMD) is Attracting Investor Attention: Here is What You Should Know

YOKNEAM, Israel , Sept. 5, 2023 /PRNewswire/ -- InMode Ltd.

InMode to Present at Upcoming Investor Conferences and Events

InMode investors experienced significant volatility as INMD was hammered after its pre-earnings surge. As a result, it nearly gave up all its July gains. Investors are likely still concerned about the impact of high interest rates on medical capital equipment spending. Also, InMode's revenue growth could slow further through 2025. Despite that, dip buyers returned with conviction over the past two weeks, likely seeing attractive value in INMD following the steep plunge.

InMode: Be Greedy When Others Are Fearful

INMD's P/E and EV/EBITDA ratios have fallen sharply in the past 2-3 years despite its revenues and net income more than doubling in this period. The prospect of continued profitable growth and a history of beating analysts' estimates suggest that this undervaluation will not persist for long. INMD has insanely high gross margins and net income margins due to unique cost advantages that competitors like Cutera and Apyx lack.

InMode: Prolonged Valuation Slump Is A Buying Opportunity

Deere & Company

Perion Network

The stock market is filled with sleeper stocks that present tempting opportunities. Some investment ideas receive much of the spotlight.

Want to Get Rich? 3 Game-Changing Sleeper Stocks to Buy Right Now

InMode Ltd. (INMD) Is a Trending Stock: Facts to Know Before Betting on It

Broadcom

Costco

Cisco Systems

Microsoft

Procter & Gamble

Visa

Forever stocks can be tough picks in today's market. The stock market goes through many twists and turns.

The 7 Most Undervalued Forever Stocks to Buy Now: August 2023

InMode continues to steadily expand its base of revenue and its market penetration. It's also becoming more profitable over time while growing.

Got $5,000? Here's 3 Reasons to Buy InMode Stock Right Now

InMode's customers need to buy consumable products to use with their devices. The more consumables the company sells, the more recurring revenue it gets.

This 1 Number Shows Why InMode Stock Is a Buy

InMode shares rose sharply in anticipation of the company's second-quarter earnings report. Soaring sales of medical devices used for minimally invasive cosmetic procedures drove profits 25% higher year over year.

Is It Too Late to Buy InMode Stock?

InMode's sales performance has been strong, and it might get still stronger soon. Popular weight-loss drugs could lead to more demand for skin tightening services.

Here's Why I'm Buying (More) InMode Stock in August

InMode Ltd. (NASDAQ:INMD ) Q2 2023 Earnings Conference Call July 27, 2023 8:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and CEO Shakil Lakhani - President, North America Yair Malca - Chief Financial Officer Spero Theodorou - Chief Medical Officer Conference Call Participants Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Jeff Johnson - Baird Mike Matson - Needham & Company Ryan Barokas - UBS Operator Good day, and welcome to the InMode Second Quarter 2023 Earnings Results Conference Call.

InMode Ltd. (INMD) Q2 2023 Earnings Call Transcript

InMode (INMD) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.70 per share. This compares to earnings of $0.59 per share a year ago.

InMode (INMD) Q2 Earnings and Revenues Beat Estimates

YOKNEAM, Israel, July 27, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2023.

InMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year Growth

Here is how InMode (INMD) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging InMode (INMD) This Year?

YOKNEAM, Israel , July 25, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to announce the completion of a significant intellectual property (IP) transaction in the women's health and wellness market.

InMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents

Investors Heavily Search InMode Ltd. (INMD): Here is What You Need to Know

I discuss the investment potential of InMode, a company specializing in laser equipment for aesthetic medicine treatments, which has seen significant growth and offers high growth prospects with attractive profit margins. My analysis of InMode's business model, competitive position, and intrinsic value suggests it is a strong investment opportunity, with a unique market position, protected by patents, and negligible debts. I conclude that despite the inherent uncertainties of any investment, the strong financials and market position of InMode make it a promising addition to their main portfolio.

InMode: A Laser-Focused Investment Opportunity

InMode released preliminary financial results that were better than what analysts expected, and management raised its full-year guidance as a result. The company has surprised the market with finalized results before, and it could do so again in a couple of weeks.

Why InMode Stock Flew to a New 52-Week High Today

InMode preannounced better-than-expected second-quarter metrics on Wednesday, pushing INMD stock into a breakout.

InMode, A Top 1% Profit Machine, Breaks Out On Solid Preannouncement — But There's A Caveat

Fortinet

ServiceNow

Investors seeking higher returns on their capital often turn to hypergrowth stocks. These assets have great potential and can comfortably exceed the returns of the S&P 500 if the companies continue to grow at high rates.

3 Hypergrowth Stocks to Catapult You into the Millionaires' Club

InMode Ltd.'s stock INMD, +2.31% rose 2.5% premarket Wednesday, after the Israeli medical tech company offered second-quarter guidance that topped estimates and raised its full-year revenue guidance.

Israeli medtech company InMode's stock up premarket after company offers guidance that tops estimates

Conference call to be held on Thursday, July 27, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 12, 2023 /PRNewswire/ -- InMode Ltd.

News for Inmode Ltd Stock (INMD)